nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—HRH1—atherosclerosis	0.468	1	CbGaD
Cyclizine—Flunarizine—Ezetimibe—atherosclerosis	0.321	1	CrCrCtD
Cyclizine—CYP2C9—Rosuvastatin—atherosclerosis	0.0371	0.267	CbGbCtD
Cyclizine—CYP2C9—Simvastatin—atherosclerosis	0.0345	0.248	CbGbCtD
Cyclizine—CYP2C9—Pravastatin—atherosclerosis	0.0337	0.243	CbGbCtD
Cyclizine—CYP2C9—Lovastatin—atherosclerosis	0.0337	0.243	CbGbCtD
Cyclizine—Jaundice cholestatic—Lovastatin—atherosclerosis	0.00131	0.0241	CcSEcCtD
Cyclizine—Jaundice cholestatic—Simvastatin—atherosclerosis	0.00123	0.0226	CcSEcCtD
Cyclizine—Jaundice cholestatic—Niacin—atherosclerosis	0.00112	0.0207	CcSEcCtD
Cyclizine—Jaundice cholestatic—Pravastatin—atherosclerosis	0.00111	0.0204	CcSEcCtD
Cyclizine—Muscle twitching—Niacin—atherosclerosis	0.00101	0.0185	CcSEcCtD
Cyclizine—Hepatic function abnormal—Lovastatin—atherosclerosis	0.000956	0.0176	CcSEcCtD
Cyclizine—Hepatic function abnormal—Simvastatin—atherosclerosis	0.000894	0.0165	CcSEcCtD
Cyclizine—Hepatic function abnormal—Niacin—atherosclerosis	0.000821	0.0151	CcSEcCtD
Cyclizine—Hepatic function abnormal—Pravastatin—atherosclerosis	0.000808	0.0149	CcSEcCtD
Cyclizine—Dermatitis bullous—Niacin—atherosclerosis	0.000751	0.0138	CcSEcCtD
Cyclizine—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000718	0.0132	CcSEcCtD
Cyclizine—Urinary retention—Niacin—atherosclerosis	0.000682	0.0126	CcSEcCtD
Cyclizine—Hepatitis—Rosuvastatin—atherosclerosis	0.000682	0.0126	CcSEcCtD
Cyclizine—Mental disorder—Rosuvastatin—atherosclerosis	0.000597	0.011	CcSEcCtD
Cyclizine—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000597	0.011	CcSEcCtD
Cyclizine—Hepatitis—Lovastatin—atherosclerosis	0.000578	0.0106	CcSEcCtD
Cyclizine—Hepatitis—Ezetimibe—atherosclerosis	0.000567	0.0104	CcSEcCtD
Cyclizine—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000557	0.0103	CcSEcCtD
Cyclizine—Angioedema—Rosuvastatin—atherosclerosis	0.000542	0.00999	CcSEcCtD
Cyclizine—Hepatitis—Simvastatin—atherosclerosis	0.000541	0.00996	CcSEcCtD
Cyclizine—Chills—Lovastatin—atherosclerosis	0.000519	0.00955	CcSEcCtD
Cyclizine—Mental disorder—Ezetimibe—atherosclerosis	0.000497	0.00915	CcSEcCtD
Cyclizine—Hepatitis—Niacin—atherosclerosis	0.000496	0.00915	CcSEcCtD
Cyclizine—Erythema—Ezetimibe—atherosclerosis	0.000493	0.00909	CcSEcCtD
Cyclizine—Hepatitis—Pravastatin—atherosclerosis	0.000489	0.009	CcSEcCtD
Cyclizine—Chills—Simvastatin—atherosclerosis	0.000485	0.00894	CcSEcCtD
Cyclizine—Muscle spasms—Lovastatin—atherosclerosis	0.000484	0.00891	CcSEcCtD
Cyclizine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000475	0.00875	CcSEcCtD
Cyclizine—Muscle spasms—Ezetimibe—atherosclerosis	0.000474	0.00874	CcSEcCtD
Cyclizine—Vision blurred—Lovastatin—atherosclerosis	0.000474	0.00874	CcSEcCtD
Cyclizine—Mental disorder—Simvastatin—atherosclerosis	0.000474	0.00873	CcSEcCtD
Cyclizine—Tremor—Lovastatin—atherosclerosis	0.000471	0.00868	CcSEcCtD
Cyclizine—Erythema—Simvastatin—atherosclerosis	0.000471	0.00867	CcSEcCtD
Cyclizine—Eye disorder—Niacin—atherosclerosis	0.000464	0.00855	CcSEcCtD
Cyclizine—Angioedema—Lovastatin—atherosclerosis	0.00046	0.00847	CcSEcCtD
Cyclizine—Muscle spasms—Simvastatin—atherosclerosis	0.000452	0.00834	CcSEcCtD
Cyclizine—Angioedema—Ezetimibe—atherosclerosis	0.000451	0.00831	CcSEcCtD
Cyclizine—Chills—Niacin—atherosclerosis	0.000445	0.00821	CcSEcCtD
Cyclizine—Vision blurred—Simvastatin—atherosclerosis	0.000443	0.00817	CcSEcCtD
Cyclizine—Tremor—Simvastatin—atherosclerosis	0.000441	0.00812	CcSEcCtD
Cyclizine—Chills—Pravastatin—atherosclerosis	0.000439	0.00808	CcSEcCtD
Cyclizine—Insomnia—Rosuvastatin—atherosclerosis	0.000438	0.00807	CcSEcCtD
Cyclizine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000435	0.00802	CcSEcCtD
Cyclizine—Erythema—Niacin—atherosclerosis	0.000432	0.00796	CcSEcCtD
Cyclizine—Angioedema—Simvastatin—atherosclerosis	0.00043	0.00792	CcSEcCtD
Cyclizine—Hypertension—Ezetimibe—atherosclerosis	0.000426	0.00785	CcSEcCtD
Cyclizine—Tension—Niacin—atherosclerosis	0.000424	0.00781	CcSEcCtD
Cyclizine—Nervousness—Niacin—atherosclerosis	0.00042	0.00773	CcSEcCtD
Cyclizine—Tension—Pravastatin—atherosclerosis	0.000417	0.00769	CcSEcCtD
Cyclizine—Phenindamine—HRH1—atherosclerosis	0.000416	0.0849	CrCbGaD
Cyclizine—Muscle spasms—Niacin—atherosclerosis	0.000415	0.00765	CcSEcCtD
Cyclizine—Pain—Rosuvastatin—atherosclerosis	0.000414	0.00763	CcSEcCtD
Cyclizine—Constipation—Rosuvastatin—atherosclerosis	0.000414	0.00763	CcSEcCtD
Cyclizine—Nervousness—Pravastatin—atherosclerosis	0.000413	0.00761	CcSEcCtD
Cyclizine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000411	0.00756	CcSEcCtD
Cyclizine—Muscle spasms—Pravastatin—atherosclerosis	0.000409	0.00754	CcSEcCtD
Cyclizine—Vision blurred—Niacin—atherosclerosis	0.000407	0.0075	CcSEcCtD
Cyclizine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000403	0.00742	CcSEcCtD
Cyclizine—Vision blurred—Pravastatin—atherosclerosis	0.000401	0.00739	CcSEcCtD
Cyclizine—Tremor—Pravastatin—atherosclerosis	0.000399	0.00734	CcSEcCtD
Cyclizine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000395	0.00728	CcSEcCtD
Cyclizine—Angioedema—Niacin—atherosclerosis	0.000395	0.00727	CcSEcCtD
Cyclizine—Skin disorder—Ezetimibe—atherosclerosis	0.000391	0.00721	CcSEcCtD
Cyclizine—Angioedema—Pravastatin—atherosclerosis	0.000389	0.00716	CcSEcCtD
Cyclizine—Dimenhydrinate—HRH1—atherosclerosis	0.000386	0.0789	CrCbGaD
Cyclizine—Urticaria—Rosuvastatin—atherosclerosis	0.000385	0.00709	CcSEcCtD
Cyclizine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000384	0.00708	CcSEcCtD
Cyclizine—Insomnia—Lovastatin—atherosclerosis	0.000371	0.00684	CcSEcCtD
Cyclizine—Paraesthesia—Lovastatin—atherosclerosis	0.000369	0.00679	CcSEcCtD
Cyclizine—Hypertension—Pravastatin—atherosclerosis	0.000367	0.00677	CcSEcCtD
Cyclizine—Insomnia—Ezetimibe—atherosclerosis	0.000364	0.00671	CcSEcCtD
Cyclizine—Paraesthesia—Ezetimibe—atherosclerosis	0.000362	0.00666	CcSEcCtD
Cyclizine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000357	0.00658	CcSEcCtD
Cyclizine—Anaphylactic shock—Niacin—atherosclerosis	0.000353	0.0065	CcSEcCtD
Cyclizine—Pain—Lovastatin—atherosclerosis	0.000351	0.00647	CcSEcCtD
Cyclizine—Constipation—Lovastatin—atherosclerosis	0.000351	0.00647	CcSEcCtD
Cyclizine—Cetirizine—HRH1—atherosclerosis	0.00035	0.0715	CrCbGaD
Cyclizine—Asthenia—Rosuvastatin—atherosclerosis	0.000348	0.0064	CcSEcCtD
Cyclizine—Insomnia—Simvastatin—atherosclerosis	0.000347	0.0064	CcSEcCtD
Cyclizine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000347	0.0064	CcSEcCtD
Cyclizine—Paraesthesia—Simvastatin—atherosclerosis	0.000345	0.00635	CcSEcCtD
Cyclizine—Antazoline—HRH1—atherosclerosis	0.000344	0.0703	CrCbGaD
Cyclizine—Pain—Ezetimibe—atherosclerosis	0.000344	0.00635	CcSEcCtD
Cyclizine—Constipation—Ezetimibe—atherosclerosis	0.000344	0.00635	CcSEcCtD
Cyclizine—Tachycardia—Niacin—atherosclerosis	0.000344	0.00634	CcSEcCtD
Cyclizine—Pruritus—Rosuvastatin—atherosclerosis	0.000343	0.00632	CcSEcCtD
Cyclizine—Skin disorder—Niacin—atherosclerosis	0.000343	0.00631	CcSEcCtD
Cyclizine—Hypotension—Niacin—atherosclerosis	0.00033	0.00607	CcSEcCtD
Cyclizine—Pain—Simvastatin—atherosclerosis	0.000328	0.00605	CcSEcCtD
Cyclizine—Constipation—Simvastatin—atherosclerosis	0.000328	0.00605	CcSEcCtD
Cyclizine—Urticaria—Lovastatin—atherosclerosis	0.000326	0.00601	CcSEcCtD
Cyclizine—Dizziness—Rosuvastatin—atherosclerosis	0.00032	0.0059	CcSEcCtD
Cyclizine—Urticaria—Ezetimibe—atherosclerosis	0.00032	0.00589	CcSEcCtD
Cyclizine—Chlorcyclizine—HRH1—atherosclerosis	0.000319	0.0652	CrCbGaD
Cyclizine—Insomnia—Niacin—atherosclerosis	0.000319	0.00588	CcSEcCtD
Cyclizine—Paraesthesia—Niacin—atherosclerosis	0.000317	0.00583	CcSEcCtD
Cyclizine—Insomnia—Pravastatin—atherosclerosis	0.000314	0.00579	CcSEcCtD
Cyclizine—Somnolence—Niacin—atherosclerosis	0.000314	0.00578	CcSEcCtD
Cyclizine—Paraesthesia—Pravastatin—atherosclerosis	0.000312	0.00574	CcSEcCtD
Cyclizine—Buclizine—HRH1—atherosclerosis	0.000307	0.0627	CrCbGaD
Cyclizine—Urticaria—Simvastatin—atherosclerosis	0.000305	0.00562	CcSEcCtD
Cyclizine—Headache—Rosuvastatin—atherosclerosis	0.000304	0.00559	CcSEcCtD
Cyclizine—Hypersensitivity—Lovastatin—atherosclerosis	0.000303	0.00557	CcSEcCtD
Cyclizine—Pain—Niacin—atherosclerosis	0.000302	0.00556	CcSEcCtD
Cyclizine—Constipation—Pravastatin—atherosclerosis	0.000297	0.00547	CcSEcCtD
Cyclizine—Pain—Pravastatin—atherosclerosis	0.000297	0.00547	CcSEcCtD
Cyclizine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000297	0.00547	CcSEcCtD
Cyclizine—Asthenia—Lovastatin—atherosclerosis	0.000295	0.00543	CcSEcCtD
Cyclizine—Meclizine—HRH1—atherosclerosis	0.000293	0.0598	CrCbGaD
Cyclizine—Pruritus—Lovastatin—atherosclerosis	0.00029	0.00535	CcSEcCtD
Cyclizine—Asthenia—Ezetimibe—atherosclerosis	0.000289	0.00532	CcSEcCtD
Cyclizine—Pheniramine—HRH1—atherosclerosis	0.000287	0.0585	CrCbGaD
Cyclizine—Pruritus—Ezetimibe—atherosclerosis	0.000285	0.00525	CcSEcCtD
Cyclizine—Hypersensitivity—Simvastatin—atherosclerosis	0.000283	0.00521	CcSEcCtD
Cyclizine—Methdilazine—HRH1—atherosclerosis	0.000281	0.0573	CrCbGaD
Cyclizine—Urticaria—Niacin—atherosclerosis	0.00028	0.00516	CcSEcCtD
Cyclizine—Urticaria—Pravastatin—atherosclerosis	0.000276	0.00508	CcSEcCtD
Cyclizine—Asthenia—Simvastatin—atherosclerosis	0.000276	0.00508	CcSEcCtD
Cyclizine—Pruritus—Simvastatin—atherosclerosis	0.000272	0.00501	CcSEcCtD
Cyclizine—Dizziness—Lovastatin—atherosclerosis	0.000272	0.005	CcSEcCtD
Cyclizine—Hydroxyzine—HRH1—atherosclerosis	0.00027	0.0552	CrCbGaD
Cyclizine—Dizziness—Ezetimibe—atherosclerosis	0.000266	0.00491	CcSEcCtD
Cyclizine—Hypersensitivity—Niacin—atherosclerosis	0.00026	0.00479	CcSEcCtD
Cyclizine—Headache—Lovastatin—atherosclerosis	0.000257	0.00474	CcSEcCtD
Cyclizine—Hypersensitivity—Pravastatin—atherosclerosis	0.000256	0.00471	CcSEcCtD
Cyclizine—Dizziness—Simvastatin—atherosclerosis	0.000254	0.00468	CcSEcCtD
Cyclizine—Asthenia—Niacin—atherosclerosis	0.000253	0.00466	CcSEcCtD
Cyclizine—Headache—Ezetimibe—atherosclerosis	0.000252	0.00465	CcSEcCtD
Cyclizine—Pruritus—Niacin—atherosclerosis	0.000249	0.0046	CcSEcCtD
Cyclizine—Asthenia—Pravastatin—atherosclerosis	0.000249	0.00459	CcSEcCtD
Cyclizine—Pruritus—Pravastatin—atherosclerosis	0.000246	0.00453	CcSEcCtD
Cyclizine—Headache—Simvastatin—atherosclerosis	0.000241	0.00443	CcSEcCtD
Cyclizine—Dizziness—Niacin—atherosclerosis	0.000233	0.0043	CcSEcCtD
Cyclizine—Dizziness—Pravastatin—atherosclerosis	0.00023	0.00423	CcSEcCtD
Cyclizine—Diphenylpyraline—HRH1—atherosclerosis	0.000227	0.0464	CrCbGaD
Cyclizine—Headache—Niacin—atherosclerosis	0.000221	0.00407	CcSEcCtD
Cyclizine—Headache—Pravastatin—atherosclerosis	0.000218	0.00401	CcSEcCtD
Cyclizine—Ifenprodil—HRH1—atherosclerosis	0.000215	0.0439	CrCbGaD
Cyclizine—Benzatropine—HRH1—atherosclerosis	0.000174	0.0356	CrCbGaD
Cyclizine—Flunarizine—HRH1—atherosclerosis	0.000158	0.0322	CrCbGaD
Cyclizine—Cyproheptadine—HRH1—atherosclerosis	0.000143	0.0292	CrCbGaD
Cyclizine—Cinnarizine—HRH1—atherosclerosis	0.000125	0.0255	CrCbGaD
Cyclizine—Prochlorperazine—HRH1—atherosclerosis	0.00012	0.0245	CrCbGaD
Cyclizine—Mianserin—HRH1—atherosclerosis	0.000108	0.0221	CrCbGaD
Cyclizine—Diphenhydramine—HRH1—atherosclerosis	8.96e-05	0.0183	CrCbGaD
Cyclizine—Loxapine—HRH1—atherosclerosis	8.61e-05	0.0176	CrCbGaD
Cyclizine—Orphenadrine—HRH1—atherosclerosis	8.47e-05	0.0173	CrCbGaD
Cyclizine—Clozapine—HRH1—atherosclerosis	7.23e-05	0.0148	CrCbGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—STAT3—atherosclerosis	4.27e-05	0.00323	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CCL4—atherosclerosis	4.12e-05	0.00311	CbGpPWpGaD
Cyclizine—Phenprocoumon—ALB—atherosclerosis	4.1e-05	0.00836	CrCbGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—MAPK3—atherosclerosis	4.08e-05	0.00308	CbGpPWpGaD
Cyclizine—HRH1—GPCRs, Class A Rhodopsin-like—EDNRA—atherosclerosis	3.9e-05	0.00295	CbGpPWpGaD
Cyclizine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—atherosclerosis	3.9e-05	0.00295	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—atherosclerosis	3.86e-05	0.00292	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—HMOX1—atherosclerosis	3.86e-05	0.00291	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—atherosclerosis	3.84e-05	0.0029	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—atherosclerosis	3.7e-05	0.00279	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—APOB—atherosclerosis	3.7e-05	0.00279	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—UTS2—atherosclerosis	3.67e-05	0.00277	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—EDN1—atherosclerosis	3.64e-05	0.00275	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LDLRAP1—atherosclerosis	3.61e-05	0.00272	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTM1—atherosclerosis	3.59e-05	0.00271	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—LPL—atherosclerosis	3.53e-05	0.00266	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CX3CR1—atherosclerosis	3.52e-05	0.00266	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CASR—atherosclerosis	3.52e-05	0.00266	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CX3CL1—atherosclerosis	3.46e-05	0.00261	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GPX1—atherosclerosis	3.44e-05	0.0026	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS2—atherosclerosis	3.43e-05	0.00259	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—atherosclerosis	3.42e-05	0.00258	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PLTP—atherosclerosis	3.39e-05	0.00256	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CD36—atherosclerosis	3.35e-05	0.00253	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—atherosclerosis	3.34e-05	0.00253	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDNRA—atherosclerosis	3.34e-05	0.00253	CbGpPWpGaD
Cyclizine—HRH1—GPCRs, Class A Rhodopsin-like—AGTR1—atherosclerosis	3.32e-05	0.00251	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CNR2—atherosclerosis	3.28e-05	0.00247	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—atherosclerosis	3.26e-05	0.00246	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—atherosclerosis	3.26e-05	0.00246	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—MTHFR—atherosclerosis	3.18e-05	0.0024	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PPARA—atherosclerosis	3.12e-05	0.00235	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—AGT—atherosclerosis	3.02e-05	0.00228	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—AGT—atherosclerosis	3.02e-05	0.00228	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—APOE—atherosclerosis	2.96e-05	0.00223	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ABCG8—atherosclerosis	2.94e-05	0.00222	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LTA4H—atherosclerosis	2.94e-05	0.00222	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CAV1—atherosclerosis	2.93e-05	0.00221	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—APOA1—atherosclerosis	2.92e-05	0.00221	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—KNG1—atherosclerosis	2.86e-05	0.00216	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR1—atherosclerosis	2.84e-05	0.00215	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CCL3—atherosclerosis	2.82e-05	0.00213	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—F2—atherosclerosis	2.79e-05	0.00211	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—AKT1—atherosclerosis	2.75e-05	0.00208	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—atherosclerosis	2.7e-05	0.00204	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PIK3CG—atherosclerosis	2.67e-05	0.00202	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PPARG—atherosclerosis	2.58e-05	0.00195	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CCR2—atherosclerosis	2.55e-05	0.00192	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—EDNRA—atherosclerosis	2.55e-05	0.00192	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—INS—atherosclerosis	2.53e-05	0.00191	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—atherosclerosis	2.5e-05	0.00189	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—GHRL—atherosclerosis	2.48e-05	0.00187	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	2.41e-05	0.00182	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	2.39e-05	0.00181	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ABCG1—atherosclerosis	2.32e-05	0.00176	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ALB—atherosclerosis	2.32e-05	0.00175	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTM1—atherosclerosis	2.27e-05	0.00171	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTM1—atherosclerosis	2.24e-05	0.00169	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NOS3—atherosclerosis	2.22e-05	0.00167	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—FABP4—atherosclerosis	2.19e-05	0.00165	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LCAT—atherosclerosis	2.19e-05	0.00165	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—KNG1—atherosclerosis	2.18e-05	0.00165	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—AGTR1—atherosclerosis	2.17e-05	0.00164	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOA4—atherosclerosis	2.15e-05	0.00162	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CCL4—atherosclerosis	2.12e-05	0.0016	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP7A1—atherosclerosis	2.11e-05	0.00159	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—UTS2—atherosclerosis	2.08e-05	0.00157	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS2—atherosclerosis	2.03e-05	0.00153	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	2e-05	0.00151	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CASR—atherosclerosis	1.99e-05	0.0015	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—atherosclerosis	1.95e-05	0.00147	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—UTS2—atherosclerosis	1.89e-05	0.00142	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CNR2—atherosclerosis	1.85e-05	0.0014	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	1.85e-05	0.0014	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOA2—atherosclerosis	1.85e-05	0.00139	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G2A—atherosclerosis	1.85e-05	0.00139	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5AP—atherosclerosis	1.85e-05	0.00139	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—atherosclerosis	1.85e-05	0.00139	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—EDN1—atherosclerosis	1.84e-05	0.00139	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—atherosclerosis	1.82e-05	0.00138	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CCL5—atherosclerosis	1.82e-05	0.00138	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CX3CR1—atherosclerosis	1.81e-05	0.00137	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CASR—atherosclerosis	1.81e-05	0.00137	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CX3CL1—atherosclerosis	1.77e-05	0.00134	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LPA—atherosclerosis	1.76e-05	0.00133	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	1.69e-05	0.00128	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CNR2—atherosclerosis	1.68e-05	0.00127	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	1.65e-05	0.00124	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	1.63e-05	0.00123	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	1.61e-05	0.00121	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	1.57e-05	0.00119	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—AGT—atherosclerosis	1.52e-05	0.00115	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PLTP—atherosclerosis	1.51e-05	0.00114	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CCL3—atherosclerosis	1.45e-05	0.00109	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CCR2—atherosclerosis	1.44e-05	0.00109	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—EDNRA—atherosclerosis	1.44e-05	0.00109	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—F2—atherosclerosis	1.41e-05	0.00106	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—GHRL—atherosclerosis	1.4e-05	0.00106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	1.4e-05	0.00106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	1.39e-05	0.00105	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	1.38e-05	0.00104	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOA4—atherosclerosis	1.36e-05	0.00102	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	1.35e-05	0.00102	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	1.35e-05	0.00102	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCG8—atherosclerosis	1.31e-05	0.000989	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LTA4H—atherosclerosis	1.31e-05	0.000989	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EDNRA—atherosclerosis	1.31e-05	0.000987	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CCR2—atherosclerosis	1.31e-05	0.000987	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	1.3e-05	0.000984	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	1.29e-05	0.000977	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—GHRL—atherosclerosis	1.27e-05	0.000962	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CCL2—atherosclerosis	1.26e-05	0.000948	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCL4—atherosclerosis	1.25e-05	0.000944	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—KNG1—atherosclerosis	1.23e-05	0.00093	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AGTR1—atherosclerosis	1.22e-05	0.000924	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	1.22e-05	0.000922	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOA2—atherosclerosis	1.17e-05	0.000882	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KNG1—atherosclerosis	1.12e-05	0.000844	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—UTS2—atherosclerosis	1.11e-05	0.000841	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AGTR1—atherosclerosis	1.11e-05	0.000839	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.09e-05	0.000822	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CX3CR1—atherosclerosis	1.07e-05	0.000806	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASR—atherosclerosis	1.07e-05	0.000806	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CX3CL1—atherosclerosis	1.05e-05	0.000791	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—EDN1—atherosclerosis	1.04e-05	0.000784	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCG1—atherosclerosis	1.04e-05	0.000782	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CCL5—atherosclerosis	1.03e-05	0.000777	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—AKT1—atherosclerosis	1.02e-05	0.000769	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CNR2—atherosclerosis	9.93e-06	0.00075	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CXCL8—atherosclerosis	9.92e-06	0.000749	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MMP3—atherosclerosis	9.91e-06	0.000748	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	9.89e-06	0.000746	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PRKCG—atherosclerosis	9.79e-06	0.000739	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LCAT—atherosclerosis	9.74e-06	0.000735	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—FABP4—atherosclerosis	9.74e-06	0.000735	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOA4—atherosclerosis	9.56e-06	0.000722	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EDN1—atherosclerosis	9.42e-06	0.000712	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP7A1—atherosclerosis	9.39e-06	0.000709	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CCL5—atherosclerosis	9.35e-06	0.000706	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	8.95e-06	0.000675	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PRKCG—atherosclerosis	8.89e-06	0.000671	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VWF—atherosclerosis	8.85e-06	0.000668	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOC3—atherosclerosis	8.8e-06	0.000664	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LDLR—atherosclerosis	8.74e-06	0.00066	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP27A1—atherosclerosis	8.68e-06	0.000655	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AGT—atherosclerosis	8.61e-06	0.00065	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	8.54e-06	0.000645	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCL3—atherosclerosis	8.54e-06	0.000645	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	8.33e-06	0.000629	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	8.23e-06	0.000621	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOA2—atherosclerosis	8.23e-06	0.000621	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALOX15—atherosclerosis	8.23e-06	0.000621	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	8.23e-06	0.000621	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NCF1—atherosclerosis	8.18e-06	0.000617	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCG5—atherosclerosis	8.12e-06	0.000614	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	8.12e-06	0.000613	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—F2—atherosclerosis	7.96e-06	0.000601	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LPA—atherosclerosis	7.85e-06	0.000593	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AGT—atherosclerosis	7.82e-06	0.000591	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EDNRA—atherosclerosis	7.72e-06	0.000583	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCR2—atherosclerosis	7.72e-06	0.000583	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CYBA—atherosclerosis	7.69e-06	0.000581	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CG—atherosclerosis	7.62e-06	0.000575	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—BGN—atherosclerosis	7.6e-06	0.000574	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	7.55e-06	0.00057	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PARP1—atherosclerosis	7.53e-06	0.000568	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GHRL—atherosclerosis	7.53e-06	0.000568	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PLAT—atherosclerosis	7.53e-06	0.000568	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOA5—atherosclerosis	7.52e-06	0.000568	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	7.31e-06	0.000552	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	7.24e-06	0.000547	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—F2—atherosclerosis	7.23e-06	0.000546	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	7.16e-06	0.000541	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	7.09e-06	0.000536	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	7.08e-06	0.000534	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALOX5—atherosclerosis	6.99e-06	0.000528	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CG—atherosclerosis	6.92e-06	0.000522	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KNG1—atherosclerosis	6.61e-06	0.000499	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AGTR1—atherosclerosis	6.57e-06	0.000496	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	6.46e-06	0.000488	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CCL2—atherosclerosis	6.44e-06	0.000486	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PLG—atherosclerosis	6.4e-06	0.000483	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAMPT—atherosclerosis	6.27e-06	0.000474	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.24e-06	0.000471	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LIPC—atherosclerosis	6.23e-06	0.000471	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOC3—atherosclerosis	6.2e-06	0.000468	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LDLR—atherosclerosis	6.16e-06	0.000465	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SOCS3—atherosclerosis	6.06e-06	0.000458	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CETP—atherosclerosis	6.01e-06	0.000454	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP3—atherosclerosis	5.85e-06	0.000442	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF2—atherosclerosis	5.83e-06	0.00044	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SCARB1—atherosclerosis	5.76e-06	0.000435	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOB—atherosclerosis	5.66e-06	0.000427	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL8—atherosclerosis	5.61e-06	0.000423	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	5.61e-06	0.000423	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EDN1—atherosclerosis	5.57e-06	0.00042	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCL5—atherosclerosis	5.52e-06	0.000417	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMGCR—atherosclerosis	5.44e-06	0.000411	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LPL—atherosclerosis	5.4e-06	0.000408	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRKCG—atherosclerosis	5.25e-06	0.000397	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SPP1—atherosclerosis	5.12e-06	0.000386	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CXCL8—atherosclerosis	5.09e-06	0.000385	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.91e-06	0.00037	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCA1—atherosclerosis	4.85e-06	0.000366	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDGFB—atherosclerosis	4.73e-06	0.000357	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AGT—atherosclerosis	4.62e-06	0.000349	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOE—atherosclerosis	4.53e-06	0.000342	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LEP—atherosclerosis	4.53e-06	0.000342	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CAV1—atherosclerosis	4.49e-06	0.000339	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APOA1—atherosclerosis	4.48e-06	0.000338	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ESR1—atherosclerosis	4.32e-06	0.000326	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—F2—atherosclerosis	4.27e-06	0.000322	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMOX1—atherosclerosis	4.16e-06	0.000314	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	4.09e-06	0.000308	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOB—atherosclerosis	3.98e-06	0.000301	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	3.91e-06	0.000295	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—atherosclerosis	3.88e-06	0.000293	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—INS—atherosclerosis	3.87e-06	0.000292	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCL2—atherosclerosis	3.81e-06	0.000287	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LPL—atherosclerosis	3.8e-06	0.000287	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.74e-06	0.000282	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPX1—atherosclerosis	3.71e-06	0.00028	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CD36—atherosclerosis	3.61e-06	0.000273	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.55e-06	0.000268	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTHFR—atherosclerosis	3.43e-06	0.000259	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.39e-06	0.000256	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARA—atherosclerosis	3.36e-06	0.000254	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AGT—atherosclerosis	3.25e-06	0.000246	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOE—atherosclerosis	3.19e-06	0.000241	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CAV1—atherosclerosis	3.16e-06	0.000239	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APOA1—atherosclerosis	3.15e-06	0.000238	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.01e-06	0.000227	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	2.91e-06	0.000219	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	2.88e-06	0.000217	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.86e-06	0.000216	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARG—atherosclerosis	2.78e-06	0.00021	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—INS—atherosclerosis	2.72e-06	0.000206	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.72e-06	0.000205	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.69e-06	0.000203	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.65e-06	0.0002	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.64e-06	0.000199	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALB—atherosclerosis	2.5e-06	0.000189	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.44e-06	0.000184	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.42e-06	0.000183	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NOS3—atherosclerosis	2.39e-06	0.00018	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.31e-06	0.000175	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.24e-06	0.000169	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.18e-06	0.000165	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.69e-06	0.000128	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.56e-06	0.000118	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.1e-06	8.29e-05	CbGpPWpGaD
